Olam Hatcheries Limited (“Olam Hatcheries”), a wholly owned subsidiary of Olam International Limited (“Olam”), a leading agri-business operating across the value chain in 70 countries, and Ceva Santé Animale S.A. (“Ceva”), a leader in innovating poultry vaccines, today jointly announced the signing of a Memorandum of Understanding (“MoU”) to further develop poultry production in Nigeria.
Ceva is currently supporting Olam’s hatchery vaccination programme for day-old-chicks (“DOC”) in its hatchery by supplying vaccine, vaccination equipment and technical assistance. Olam inaugurated its US$150 million state-of-the-art poultry feed mill and DOC facilities in Kaduna State in September 2017.
The MoU will see the formation of a joint committee consisting of experts and managers from Ceva and Olam to explore four main potential areas of collaboration and technical cooperation, specifically:
- Upgrading of Olam’s Veterinary Diagnostic Laboratory (“Lab”) at Kaduna to become a reference Lab for Sub-Saharan Africa
- Development of new private labs in other regions of Nigeria to provide cost-effective and timely diagnostic support for Poultry and other animal husbandry farms
- Training of Olam’s managers and field employees by Ceva on proper vaccination techniques, on-farm diagnosis and Lab analysis, with an option for the training to be extended to select customers of Olam’s feed and DOC at a later stage
- Setting up of research projects locally and internationally involving other scientific partners for deeper epidemiological evaluation of diseases and appropriate solutions for Nigeria’s poultry sector
Sharad Gupta, Senior Vice President of Olam Grains and Head of Animal Feeds & Protein, explained the rationale for the partnership: “Our collaboration with Ceva is timely as Olam Grains scales our animal feed operations in Nigeria and beyond. As commercial poultry production in Nigeria experiences rapid growth, so does the need for vital veterinary and scientific support. Ceva brings its expertise in vaccination to our hatcheries, allowing purchasers of DOCs to be even more assured of safety and quality.”
Dr Marc Prikazsky, Chairman and CEO of Ceva, commented: “We are delighted to be partnering Olam in its journey to grow its animal feeds operations. This partnership is very much in line with our ‘Together, beyond animal health’ vision, one key element of which is to help ensure the supply of healthy food for a growing world population. It also continues our history of investment in Africa, where leading countries such as Nigeria will need to deploy the latest available agricultural technologies to maximise the production of food in-country.”
The two companies will bring a network of international partners, including the National Veterinary School of Toulouse, France and local experts, to develop training programmes for managers and technicians in the poultry sector in Nigeria. The partnership will also make available all scientific data to the wider veterinary community, to strengthen epidemiological evaluation and simplify the search for appropriate solutions.
About Olam International Limited
Olam International is a leading agri-business operating across the value chain in 70 countries, supplying various products across 18 platforms to 23,000 customers worldwide. From a direct sourcing and processing presence in most major producing countries, Olam has built a global leadership position in many of its businesses. Headquartered in Singapore and listed on the SGX-ST on February 11, 2005, Olam currently ranks among the top 30 largest primary listed companies in Singapore in terms of market capitalisation. In 2016, Fortune magazine recognised Olam at #23 in its ‘Change the World’ list. More information on Olam can be found at www.olamgroup.com.
About Ceva Santé Animale S.A.
Ceva was founded in 1999 and is a global veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Vaccines make up close to 50% of Ceva’s sales. Its headquarters are in Libourne, France. The company employs more than 5,500 people, is present in 45 countries and had sales of €1.1 billion in 2017.